Asthma Clinical Trial
Official title:
Minimal Important Difference of Walking Test in Subjects With Bronchial Asthma
The Six Minute Walking Test (6MWT) efficiently represents the exercise capacity in subjects with chronic respiratory disease, as asthma. The variation of the walking distance is a parameter used to evaluate the effectiveness of pharmacologic ando non-pharmacologic interventions, as Pulmonary Rehabilitation (PR). However, statistically significant changes in the walking distance do not always represent clinically significant variations.The aim of this prospective study is to determine the Minimal Important Difference (MID) for the 6MWT in subjects affected by asthma, regardless of the severity of the disease.
The Six Minute Walking Test (6MWT) efficiently represents the exercise capacity in subjects
with chronic respiratory disease, as asthma. The variation of the walking distance is a
parameter used to evaluate the effectiveness of pharmacologic and non-pharmacologic
interventions, asPulmonary Rehabilitation (PR). However, statistically significant changes in
the walking distance do not always represent clinically significant variations. For this
reason, it is important to understand in terms of clinical impact, how to interpret the 6MWT
when the walking distance changes over time in the same subject (for example, at the
beginning and after PR) or when it differs between subjects (some subjects may improve more
and some subjects less). It is not enough to state that the intervention works, it is
necessary to say how much it works. The demonstration of a clinically relevant effect must be
the primary goal of every treatment. A clinically relevant effect is defined as the minimum
achievable benefit, which may lead the medical doctor to change his strategy towards the
patient, for example by recommending a particular therapy or treatment. The international
scientific community calls the minimum achievable benefit with different names; one of the
most common is the Minimal Important Difference (MID). The identification of MID is relevant
for the clinician, for the agency that is paying the treatment, for the Regulatory Agency and
is equally important for the patient for whose health these groups are responsible. MID for
6MWT has been estimated in subjects with different respiratory diseases and not. In Chronic
Obstructive Pulmonary Diseases, a variation of 25 meters is considered significant. Recent
studies have shown that asthmatic subjects cover a distance of about 500 meters during 6MWT,
and that this distance improves after PR on average of 30-60 meters. Up to-day, however, the
6MWT MID in asthmatic patients has not been investigated.
The aim of this prospective study is to determine the MID for the 6MWT in subjects affected
by asthma, regardless of the severity of the disease.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|